INCB 50465

Drug Profile

INCB 50465

Alternative Names: INCB-050465; INCB-50465

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Incyte Corporation
  • Class Antineoplastics
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Myelofibrosis
  • Phase I/II B cell lymphoma; Solid tumours

Most Recent Events

  • 01 Dec 2016 Phase-II clinical trials in Diffuse large B cell lymphoma (Monotherapy, Second-line therapy or greater) in USA (PO) (NCT02998476)
  • 01 Jun 2016 Phase-II clinical trials in Myelofibrosis (Combination therapy) in USA (PO) (NCT02718300)
  • 16 Apr 2016 Efficacy, safety and pharmacokinetics data from phase I portion of a phase I/II study in B-cell lymphoma presented at the 107th Annual Meeting of the American Association of Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top